Regular Scientific Articles
Levi S, Beardshall K, Swift I, Foulkes W, Playford R, Ghosh P, Calam J. Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism. BMJ. 1989 Dec 16;299(6714):1504-5.
Foulkes WD, Rees J and Sewry C: Influenza A and rhabdomyolsis. J Infect., 1990 21: 303‑304.
Foulkes WD, Sewry C, Calam J and Hodgson HJF: Rhabdomyolysis after intramuscular iron‑dextran in malabsorption. Ann Rheum Dis., 1991 50: 184‑186.
Campbell IG, Jones TA, Foulkes WD, Trowsdale J.Folate-binding protein is a marker for ovarian cancer. Cancer Res. 1991 Oct 1;51(19):5329-38.
Foulkes WD, Campbell IG, Stamp GW, Trowsdale J.Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer. 1993 Feb;67(2):268-73.
Foulkes WD, Ragoussis J, Stamp GW, Allan GJ, Trowsdale J. Frequent loss of heterozygosity on chromosome 6 in human ovarian carcinoma. Br J Cancer. 1993 Mar;67(3):551-9.
Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest. 1993 May;91(5):2194-206.
Foulkes WD, Black DM, Stamp GW, Solomon E, Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer. 1993 May 8;54(2):220-5.
Foulkes WD, Englefield P, Campbell IG. Mutation analysis of RASK and the 'FLR exon' of NF1 in sporadic ovarian carcinoma. Eur J Cancer. 1994;30A(4):528-30.
Allan GJ, Cottrell S, Trowsdale J, Foulkes WD. Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in APC at 5q21-22. Hum Mutat. 1994;3(3):283-91.
Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K, Bast RC Jr, Solomon E. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet. 1994 Apr;3(4):589-94.
Englefield P, Foulkes WD, Campbell IG. Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12. Br J Cancer. 1994 Nov;70(5):905-7.
Campbell IG, Foulkes WD, Senger G, Trowsdale J, Garin-Chesa P, Rettig WJ.Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: a novel member of the immunoglobulin superfamily. Cancer Res. 1994 Nov 15;54(22):5761-5.
Foulkes WD, Stamp GW, Afzal S, Lalani N, McFarlane CP, Trowsdale J, Campbell IG. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer. 1995 Oct;72(4):883-8.
Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp, G, Signer, E and Jeffreys A: A somatic BRCA1 mutation in an ovarian tumour. Nature Genetics, 1995 9:343-344.
Foulkes WD and Narod SA: Hereditary breast and ovarian cancer. Clin Invest Med., 1995 18: 473-484.
Foulkes WD: A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. Q J M, 1995 88: 853-863.
Flanders T and Foulkes WD: Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet., 1996, 33:889-898.
Campbell IG, Foulkes WD, Beynon G, Davis M, Englefield P. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer. 1995 Oct 9;63(2):222-5. Erratum in: Int J Cancer 1996 Mar 1;65(5):713.
Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL. Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. Int J Cancer. 1995 Dec 11;63(6):769-73.
Foulkes WD, Narod SA. Screening for cancer in high-risk families. Cancer Treat Res. 1996;86:165-82. Review.
Afzal S, Lalani el-N, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M, Stamp GW. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest. 1996 Feb;74(2):406-21.
Bryan EJ, Watson RH, Davis M, Hitchcock A, Foulkes WD, Campbell IG. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res. 1996 Feb 15;56(4):719-21.
Davis M, Hitchcock A, Foulkes WD, Campbell IG. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res. 1996 Feb 15;56(4):741-4.
Rosenblatt DS, Foulkes WD, Narod SA. Genetic screening for breast cancer. N Engl J Med. 1996 May 2;334(18):1200-1.
Foulkes WD, Bolduc N, Lambert D, Ginsburg O, Olien L, Yandell DW, Tonin PN, Narod SA Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon. J Med Genet. 1996 Jul;33(7):534-9.
Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ. 1996 Sep 21;313(7059):716-21.
Foulkes WD. Pitfalls of genetic testing. N Engl J Med. 1996 Oct 17;335(16):1235-6; author reply 1236-7.
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE, et al.Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov;2(11):1179-83. Review.
Flanders TY, Foulkes WD. Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet. 1996 Nov;33(11):889-98. Review.
Cutler C, Foulkes WD, Brunet JS, Flanders TY, Shibata H, Narod SA.Cutaneous malignant melanoma in women is uncommonly associated with a family history of melanoma in first-degree relatives: a case-control study. Melanoma Res. 1996 Dec;6(6):435-40.
Milner BJ, Hosking L, Sun S, Haites NE, Foulkes WD. Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours. Eur J Cancer. 1996 Dec;32A(13):2360-3.
Foulkes WD, Narod SA. Ovarian cancer risk and family history. Lancet. 1997 Mar 22;349(9055):878.
Brunet JS, Narod SA, Tonin P, Foulkes WD. BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med. 1997 Apr 24;336(17):1256; author reply 1256-7.
Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997 Aug 1;80(3):435-41.
Foulkes WD. Breast cancer genetics. Lancet. 1997 Aug 2;350(9074):366.
Foulkes WD, Narod SA. Re: "Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States". Am J Epidemiol. 1997 Aug 15;146(4):364.
Foulkes WD, Buu PN, Filiatrault D, Leclerc JM, Narod SA. Excess of congenital abnormalities in French-Canadian children with neuroblastoma: a case series study from Montréal. Med Pediatr Oncol. 1997 Oct;29(4):272-9.
Bignell GR, Canzian F, Shayeghi M, Stark M, Shugart YY, Biggs P, Mangion J, Hamoudi R, Rosenblatt J, Buu P, Sun S, Stoffer SS, Goldgar DE, Romeo G, Houlston RS, Narod SA, Stratton MR, Foulkes WD. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet. 1997 Nov;61(5):1123-30
Sun S, Pollock PM, Liu L, Karimi S, Jothy S, Milner BJ, Renwick A, Lassam NJ, Hayward NK, Hogg D, Narod SA, Foulkes WD. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer. 1997 Nov 14;73(4):531-6.
Foulkes WD: Inherited susceptibility to squamous cell carcinoma of the head and neck. Ann Cancer Control Res., 1997, 7: 492-498.
Foulkes WD, Flanders TY, Pollock PM and Hayward NK: CDKN2A and cancer. Molecular Med., 1997, 3: 4-19.
Druker HA, Kasprzak L, Bégin LR, Jothy S, Narod SA and Foulkes WD: A family with Graves’ disease, multinodular goiter, non-medullary thyroid carcinoma and alveolar rhabdomyosarcoma. Am J Med Genet, 1997, 72: 30-33.
Foulkes WD, Wong N, Brunet JS, Bégin LR, Zhang JC, Martinez JJ, Rozen F, Tonin PN, Narod SA, Karp SE, Pollak MN. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2465-9.
Foulkes WD. BRCA1 and BRCA2: penetrating the clinical arena. Lancet, 1998, 352: 1325-1326.
Redston M, Nathanson KC, Yuan ZQ, Neuhausen SL, Satagopan J,Wong N, Abrahamson J, Yang D, Nafa D, Antin-Ozerkis D,Ozcelik H, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King M-C, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W and Offit K: The APC I1307K allele and breast cancer risk. Nature Genetics, 1998, 20; 13-14.
de Andrade M, Amos CI, Foulkes WD. Segregation analysis of squamous cell carcinoma of the head and neck: evidence for a major gene determining risk. Ann Hum Genet. 1998 Nov;62(Pt 6):505-10.
Liede A, Tonin PN, Sun CC, Serruya C, Daly MB, Narod SA, Foulkes WD. Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet. 1998 Jan 6;75(1):55-8.
Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, Gill S, Biggs P, Dearnaley D, Ardern-Jones A, Dowe A, Shearer R, McLellan DL, Norman RL, Ghadirian P, Aprikian A, Ford D, Amos C, King TM, Labrie F, Simard J, Narod SA, Easton D, Foulkes WD. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet. 1998 Mar;62(3):653-8. Erratum in: Am J Hum Genet. 2006 Jun;78(6):1097. McLennan, DL [corrected to McLellan, DL].
Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat. 1998;11(6):424-31.
Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costalas J, Godwin A, Olopade OI, Moslehi R, Liede A, Futreal PA, Weber BL, Lenoir GM, Lynch HT, Narod SA. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst. 1998 May 20;90(10):761-6.
Foulkes WD, Wong N, Rozen F, Brunet JS, Narod SA. Survival of patients with breast cancer and BRCA1 mutations. Lancet. 1998 May 2;351(9112):1359-60.
Kerr B, Foulkes WD, Cade D, Hadfield L, Hopwood P, Serruya C, Hoare E, Narod SA, Evans DG. False family history of breast cancer in the family cancer clinic. Eur J Surg Oncol. 1998 Aug;24(4):275-9.
Godard B, Foulkes WD, Provencher D, Brunet JS, Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol. 1998 Aug;179(2):403-10.
Foulkes WD, Wong N, Brunet JS, Narod SA. BRCA mutations and survival in breast cancer. J Clin Oncol. 1998 Sep;16(9):3206-8.
Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA.Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998 Nov;63(5):1341-51.
Foulkes WD.BRCA1 and BRCA2: penetrating the clinical arena. Lancet. 1998 Oct 24;352(9137):1325-6.
Yuan ZQ, Kasprzak L, Gordon PH, Pinsky L, Foulkes WD. I1307K APC and hMLH1 mutations in a non-Jewish family with hereditary non-polyposis colorectal cancer. Clin Genet. 1998 Oct;54(4):368-70.
Pal T, Flanders T, Mitchell-Lehman M, MacMillan A, Brunet JS, Narod SA, Foulkes WD. Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet. 1998 Dec;35(12):978-84.
Yuan ZQ, Wong N, Foulkes WD, Trifiro M, Alpert L, Manganaro F, Andreutti-Zaugg C, Iggo R, Pinsky L, Gordon P and Lasko D: A missense mutation in both hMSH2 and APC in an HNPCC kindred: implications for clinical screening. J Med Genet, 1999, 36: 790-793.
Kasprzak L, Foulkes WD, Shelling AN. Forth nightly review: hereditary ovarian carcinoma. BMJ. 1999 Mar 20;318(7186):786-9. Review.
Pereira P, Stanton V, Jothy S, Tomlinson IP, Foulkes WD, Rozen R.Loss of heterozygosity of methylenetetrahydrofolate reductase in colon carcinomas. Oncol Rep. 1999 May-Jun;6(3):597-9.
Wang ZJ, Churchman M, Campbell IG, Xu WH, Yan ZY, McCluggage WG, Foulkes WD, Tomlinson IP. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer. 1999 Apr;80(1-2):70-2.
Hamel N, Manning A, Black MJ, Tonin PN and Foulkes WD: An absence of founder BRCA2 mutations in individuals with squamous cell carcinoma of the head and neck. Int J Cancer (Pred. Oncol), 1999 83: 803-804.
Foulkes WD, Brunet J-S, Warner E, Goodwin P, Meschino W, Narod SA, Goss PE and Glendon G. The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet 1999, 65: 1776-1779.
Jefferies S, Eeles R, Goldgar D, A’Hern R, Henk JM, Gore M, Rhys-Evans P, Archer D,Bishop K, Murkin A, Solomon E, Hodgsun S, O’Connell M, Hibbert J, Easton D and Foulkes W. The role of genetic factors in predisposition to squamous cell cancer of the head and neck. Br J Cancer 1999, 79: 865-7.
Chappuis PO, Rosenblatt J and Foulkes WD: The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 1999, 10: 1163-1170.
Chappuis PO, Narod SA, Foulkes WD. Screening for ovarian cancer. Lancet. 1999 Aug 7;354(9177):509-10.
Yuan ZQ, Bégin LR, Wong N, Brunet JS, Trifiro M, Gordon PH, Pinsky L, Foulkes WD. The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer. Br J Cancer. 1999 Nov;81(5):850-4.
Jernström H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999 Nov 27;354(9193):1846-50.
Hamel N, Black MJ, Ghadirian P, Foulkes WD. No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer. 2000 Feb;82(4):757-9.
Rahman N, Arbour L, Houlston R, Bonaïti-Pellié C, Abidi F, Tranchemontagne J, Ford D, Narod S, Pritchard-Jones K, Foulkes WD, Schwartz C, Stratton MR. Penetrance of mutations in the familial Wilms tumor gene FWT1. J Natl Cancer Inst. 2000 Apr 19;92(8):650-2.
Kuperstein G, Foulkes WD, Ghadirian P, Hakimi J, Narod SA. A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet. 2000 Mar;57(3):213-20.
Chappuis PO, Deschênes J, Foulkes WD. Long-term outcome of invasive breast cancer. Lancet. 2000 Apr 29;355(9214):1551; author reply 1552-3.
Chappuis PO, Foulkes WD. Commentary on “Prevalence of BRCA1 and BRCA2 mutations in unselected male breast cancer patients in Canada”. Clinical Breast Cancer 2000, 1: 64-65.
Badzioch, M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar DE, Hopper J, Bishop DT, Moller P, Heimdal K, Easton D, the CRC/BPG UK Familial Prostate Cancer Study Group, the EU Biomed Collaborators and Simard J. Suggestive evidence for a site-specific prostate cancer gene on chromosome 1p36. J Med Genet, 2000 37: 947-949.
Singh R, Eeles RA, Durocher F, Simard J, Edwards S, Badzioch, Kote-Jarai Z, Teare D, Ford D, Dearnley D, Arden-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Labrie F, Easton DF, Narod SA, Tonin PN and Foulkes WD. High risk genes predisposing to prostate cancer development: do they exist? Prostate Cancer and Prostate Diseases 2000, 3, 241-247.
Chappuis PO, Nethercot V and Foulkes WD: Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000, 18: 287-295.
Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.Ann Oncol. 2000 Mar;11(3):307-13.
Liu G, Ghadirian P, Vesprini D, Hamel N, Paradis AJ, Lal G, Gallinger S, Narod SA, Foulkes WD. Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma. Br J Cancer. 2000 May;82(10):1646-9.
Hamel N, Karimi S, Hébert-Blouin MN, Brunet JS, Gilfix B, Ghadirian P, Black MJ, Narod SA, Foulkes WD. Increased risk of head and neck cancer in association with GSTT1 nullizygosity for individuals with low exposure to tobacco. Int J Cancer. 2000 Aug 1;87(3):452-4.
Metcalfe KA, Liede A, Hoodfar E, Scott A, Foulkes WD, Narod SA. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.J Med Genet. 2000 Nov;37(11):866-74.
Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000 Dec 15;18(24):4045-52.
Chappuis PO, Hamel N, Paradis AJ, Deschênes J, Tonin PN, Ghadirian P, Foulkes WD. Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2001 Jan 17;93(2):152-4.
Tonin PN, Perret C, Lambert JA, Paradis AJ, Kantemiroff T, Benoît MH, Martin G, Foulkes WD, Ghadirian P. Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. Int J Cancer. 2001 May 20;95(3):189-93.
Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res. 2001 May 15;61(10):4092-7.
Chappuis PO, Hamel N, Paradis AJ, Deschênes J, Robidoux A, Potvin C, Cantin J, Tonin P, Ghadirian P, Foulkes WD. Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer. Clin Genet. 2001 Jun;59(6):418-23.
Bevan S, Pal T, Greenberg CR, Green H, Wixey J, Bignell G, Narod SA, Foulkes WD, Stratton MR, Houlston RS. A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1. J Clin Endocrinol Metab. 2001 Aug;86(8):3701-4.
Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson AM, Foulkes WD, Wang T, Morgan K, Fujiwara TM, Tonin PN. Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered. 2001;52(2):116-20.
Julian-Reynier CM, Bouchard LJ, Evans DG, Eisinger FA, Foulkes WD, Kerr B, Blancquaert IR, Moatti JP, Sobol HH. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer. 2001 Aug 15;92(4):959-68.
Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin AK, Risch H, Garber J, Lerman C, Olopade OI, Foulkes WD, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé MP, Kieback DG, Narod SA. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics. 2001 Oct;11(7):635-8.
Pal T, Vogl FD, Chappuis PO, Tsang R, Brierley J, Renard H, Sanders K, Kantemiroff T, Bagha S, Goldgar DE, Narod SA, Foulkes WD. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab. 2001 Nov;86(11):5307-12.
Goffin J, Chappuis PO, Wong N, Foulkes WD. Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst. 2001 Nov 21;93(22):1754-5.
Elhaji YA, Gottlieb B, Lumbroso R, Beitel LK, Foulkes WD, Pinsky L, Trifiro MA. The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat. 2001 Nov;70(2):109-16.
Kasprzak L, Nolet S, Gaboury L, Pavia C, Villabona C, Rivera-Fillat F, Oriola J, Foulkes WD. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 2001 38: 784-787.
Chappuis PO, Ghadirian P and Foulkes WD: The role of genetic factors in the etiology of pancreatic adenocarcinoma: An update. Cancer Invest 2001, 19: 63-75.
Rabelo R, Foulkes WD, Gordon PH , Wong N, Yuan ZQ, Chong G, MacNamara E, Pinsky L and Lasko D. Genetic testing in high risk, hereditary colorectal cancer syndromes. Dis Colon Rectum 2001, 44: 437-46.
Wong N, Lasko D, Rabelo R, Pinsky L, Gordon PH and Foulkes WD. Genetic counseling and interpretation of genetic tests in hereditary non-polyposis colorectal cancer syndromes Dis Colon Rectum 2001, 44: 271-9.
Jefferies S and Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncology 2001, 37: 115-126.
Shelling AN, Foulkes WD. The molecular genetics of ovarian cancer. Mol Biotechnol 2001, 19: 13-28.
Foulkes WD, Rosenblatt J, Chappuis PO The contribution of inherited factors to the clinicopathological features and behavior of breast cancer. J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):453-65. Review.
Chappuis PO, Foulkes WD. Risk assessment & genetic testing. Cancer Treat Res. 2002;107:29-59. Review.
Yuan ZQ, Gottlieb B, Beitel LK, Wong N, Gordon PH, Wang Q, Puisieux A, Foulkes WD, Trifiro M.Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. Hum Mutat. 2002 Feb;19(2):108-13.
Hébert-Blouin MN, Koufogianis V, Gillett P, Foulkes WD. Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. Am J Obstet Gynecol. 2002 Jan;186(1):53-4.
Foulkes WD. Of mice and women. Cancer Cell 2002, 1: 11-12,.
Foulkes WD. Polygenic or Pollyanna? Nature Medicine, 2002, 8: 328-330.
Hébert-Blouin M-H, Koufogianis V, Gillett P and Foulkes WD: Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. Am J Obstet Gynecol 2002 186: 53-4.
Foulkes WD, Brunet J-S, Wong N, Goffin J and Chappuis PO. Change in the penetrance of founder BRCA1/2 mutations? A retrospective cohort study. J Med Genet 2002 39: 407-409.
Al-Saffar M and Foulkes WD: Hereditary ovarian cancer due to a non-ovarian cancer cluster region (OCCR) BRCA2 mutation: Is the OCCR useful clinically? J Med Genet 2002 39(11): e68.
Al Moustafa AE, Alaoui-Jamali MA, Batist G, Hernandez-Perez M, Serruya C, Alpert L, Black MJ, Sladek R, Foulkes WD. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene. 2002 Apr 18;21(17):2634-40.
Hutter P, Wijnen J, Rey-Berthod C, Thiffault I, Verkuijlen P, Farber D, Hamel N, Bapat B, Thibodeau SN, Burn J, Wu J, MacNamara E, Heinimann K, Chong G, Foulkes WD. An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1. J Med Genet. 2002 May;39(5):323-7.
Laaziri K, Sutton M, Ghadirian P, Scott AS, Paradis AJ, Tonin PN, Foulkes WD.Is there a correlation between the structure of hair and breast cancer or BRCA1/2 mutations? Phys Med Biol. 2002 May 21;47(10):1623-32.
Foulkes WD, Brunet JS, Wong N, Goffin J, Chappuis PO.Change in the penetrance of founder BRCA1/2 mutations? A retrospective cohort study. J Med Genet. 2002 Jun;39(6):407-9.
Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002 Aug;39(8):608-10.
Ah Mew N, Hamel N, Galvez M, Al-Saffar M, Foulkes WD Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins. Clin Genet. 2002 Aug;62(2):151-6.
Foulkes WD, Goffin J, Brunet JS, Bégin LR, Wong N, Chappuis PO. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status. J Natl Cancer Inst. 2002 Oct 2;94(19):1504-6.
Maillet P, Bonnefoi H, Vaudan-Vutskits G, Pajk B, Cufer T, Foulkes WD, Chappuis PO, Sappino AP. Constitutional alterations of the ATM gene in early onset sporadic breast cancer. J Med Genet. 2002 Oct;39(10):751-3.
Straume O, Chappuis PO, Salvesen HB, Halvorsen OJ, Haukaas SA, Goffin JR, Bégin LR, Foulkes WD, Akslen LA. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res. 2002 Dec 1;62(23):6808-11.
Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B, Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P, Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E, Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, Brunet JS.Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 4;94(23):1773-9.
Karakiewicz PI, Foulkes WD, Tanguay S, Elhilali MM, Aprikian AG. Familial prostate and breast cancer in men treated with prostatectomy for prostate cancer: a population based case-control study. J Urol, 2003 169: 240-4.
Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet J-S, Hamel N, Paradis A-J, Boyd J, Foulkes WD. The impact of germ-line BRCA1 mutations and over-expression of p53 on prognosis and response to treatment following breast cancer: 10 year follow up data. Cancer, 2003 97: 527-536.
Guillem JG, Rapaport BS, Kirchhoff T, Kolchana P, Nafa K, Glogowski E, Finch R, Huang H, Foulkes WD, Markowitz A, Ellis NA and Offit K. A636P is associated with early-onset colorectal cancer in Ashkenazi Jews. J Am Coll Surg, 2003 196:222-225.
Goffin JR, Straume O, Chappuis PO, Brunet J-S, Bégin LR, Hamel N, Wong N, Akslen LA and Foulkes WD. Glomeruloid Microvascular Proliferation is associated with p53 overexpression, germ-line BRCA1 mutations and an adverse outcome following breast cancer Br J Cancer, 2003 89: 1031-1034.
Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Bégin LR, Brunet J-S and Narod SA. Disruption of the expected positive correlation between tumor size and nodal status in BRCA1-related breast cancer. Cancer, 2003 98: 1569-1577.
Foulkes WD, Stefansson IM, Chappuis, PO Bégin LR, Goffin JR, Wong N, Trudel M and Akslen LA. Germ-line BRCA1 mutations and the basal epithelial phenotype of breast cancer. J Natl Cancer Inst, 2003 95: 1482-1485.
Pollak MN, Foulkes WD. Challenges to cancer control by screening. Nat Rev Cancer, 2003 3: 297-303.
Halford SE, Sawyer EJ, Lambros MB, Gorman P, Macdonald ND, Talbot IC, Foulkes WD, Gillett CE, Barnes DM, Akslen LA, Lee K, Jacobs IJ, Hanby AM, Ganesan TS, Salvesen HB, Bodmer WF, Tomlinson IP, Roylance RR. MSI-low, a real phenomenon which varies in frequency among cancer types. J Pathol, 2003 201: 389-394.
Edwards S, Meitz J, Eles R, Evans C, Easton D, Hopper J, Giles G, Foulkes WD, Narod S, Simard J, Badzioch M, Mahle L; International ACTANE Consortium. Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate, 2003 57: 270-9.
Hashibe M, Brennan P, Strange RC, Bhisey R, Cascorbi I, Lazarus P, Oude Ophuis MB, Benhamou S, Foulkes WD, Katoh T, Coutelle C, Romkes M, Gaspari L, Taioli E and Boffeta P. Meta and pooled analyses of GSTM1, GSTT1,GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev, 2003 12: 1509-17.
Kotar K, Hamel N, Thiffault I, Foulkes WD. The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet 2003 40: e22.
Hamel N, Kotar K, Foulkes WD. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet 2003 4: 7.
Foulkes WD, Narod SA, Swenerton K, Panabaker K, Gilbert L Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst. 2003 Nov 5;95(21):1640.
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer, 2004 4: 665-76.
Thiffault I, Hamel N, Pal T, McVety S, Marcus VA, Farber D, Cowie S, Deschenes J, Meschino W, Odefrey F, Goldgar D, Graham T, Narod S, Watters AK, MacNamara E, Sart DD, Chong G, Foulkes WD. Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. Br J Cancer, 2004 90: 483-491.
Thiffault I, Foulkes WD, Marcus VA, Farber D, Kasprzak L, MacNamara E, Wong N, Hutter P, Radice P, Bertario L, Chong G. Putative common origin of two MLH1 mutations in Italian-Quebec hereditary non-polyposis colorectal cancer families. Clin Genet, 2004 66: 137-43.
Matakidou A, Hamel N, Polpat S, Henderson K, Kantemiroff T, Harmer C, Clarke SE, Houlston RS, and Foulkes WD. Risk of non-medullary thryoid cancer influenced by polymorphic variation in the thyroglobulin gene. Carcinogenesis, 2004 25: 369-73.
Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6(1):R8-R17.
Hashibe M, Brennan P, Strange RC, Bhisey R, Cascorbi I, Lazarus P, Oude Ophuis MB, Benhamou S, Foulkes WD, Katoh T, Coutelle C, Romkes M, Gaspari L, Taioli E, Boffetta P. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer.Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1509-17.
Bouchard L, Blancquaert I, Eisinger F, Foulkes WD, Evans G, Sobol H, Julian-Reynier C. Prevention and genetic testing for breast cancer: variations in medical decisions.Soc Sci Med. 2004 Mar;58(6):1085-96.
Al Moustafa AE, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron J, Batist G, Alpert L, Alaoui-Jamali MA. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene. 2004 Jan 15;23(2):350-8.
Foulkes WD. BRCA1 functions as a breast stem cell regulator. J Med Genet. 2004 Jan;41(1):1-5.
Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA.The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004 Feb 1;64(3):830-5.
Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA.Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004 Mar 15;10(6):2029-34
Ghadirian P, Lubinski J, Lynch H, Neuhausen SL, Weber B, Isaacs C, Baruch RG, Randall S, Ainsworth P, Friedman E, Horsman D, Tonin P, Foulkes WD, Tung N, Sun P, Narod SA.Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer. 2004 Jun 20;110(3):413-6. Erratum in: Int J Cancer. 2005 May 10;114(6):1016.
Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8.
Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA.Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene. 2004 Jul 1;23(30):5252-6.
Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Møller P, Maehle L, Badzioch M, The Cancer Research UK/British Association of Urological Surgeons’ Section of Oncology Collaborators, Eeles RA, Easton DF, English DR, Southey M, Hopper JL, Foulkes WD, Giles GG. Macrophage Scavenger Receptor 1 (MSR1) 999C>T (R293X) mutation and risk of prostate cancer. Cancer Epidemiol Biomark Prevent, 2005 14: 397-402. (WDF is corresponding author).
Kasprzak L, Mesurolle B, Tremblay F, Galvez M, Halwani F, Foulkes WD. Invasive breast cancer following bilateral subcutaneous mastectomy in a BRCA2 mutation carrier: a case report and review of the literature. World J Surg Oncol 3:52, 2005.
Rudkin TM, Foulkes WD. BRCA2: breaks, mistakes and failed separations. Trends Mol Med. 2005 11(4):145-8.
Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McClennan J, Sun P, Narod SA. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers corresponding. Gynecol Oncol, 2005 96 (1): 222-6.
Chappuis PO, Donato E, Goffin JR, Wong N, Begin LR, Kapusta LR, Brunet JS,Porter P, Foulkes WD. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol, 2005 16 (5): 735-742.
Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA. A Basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev, 2005 14 (5): 1108-12.
Makriyianni I, Hamel N, Ward S, Foulkes WD, Graw S. BRCA1:185delAG found in the San Luis Valley probably originated in a Jewish founder. J Med Genet, 2005 42 (5): e27, (WDF is corresponding author).
Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res, 2005 11(11): 4003-11.
Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, Isaacs C, Kim-Sing C, Moller P, Neuhausen SL, Metcalfe K, Sun P, Narod SA. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev, 2005 14 (6): 1534-8.
Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes WD, Chan M, Turner F, Bishop DT. Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer, 2005 15: 104 (4): 719-29.
Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S,Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLj, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D; ACTANE Consortium. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet, 2005 77 (2): 219-29.
Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control, 2005 16 (6): 667-674.
McVety S, Younan R, Li L, Gordon PH, Wong N, Foulkes WD, Chong G. Novel genomic insertion-- deletion in MLH1: possible mechanistic role for non-homologous end-joining DNA repair. Clin Genet, 2005 68 (3): 234-238.
Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P, Narod SA. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res, 2005 7 (5): R833-R843.
Sun S, Greenwood CM, Thiffault I, Hamel N, Chong G, Foulkes WD. The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. J Med Genet, 2005 42 (10): 766-768.
Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA. Breast cancer risk following bilateraloophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol, 2005 23 (30): 7491-6.
Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, Friedman E, Randall S, Pasini B, Ainsworth P, Gershoni-Baruch R, Foulkes WD, Klijn J, Tung N, Rennert G, Olopade O, Couch F, Wagner T, Olsson H, Sun P, Weitzel JN, Narod SA. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer, 2005 117 (6): 988-91.
Honrado E, Osorio A, Palacios J, Milne RL, Sanchez L, Diez O, Cazorla A, Syrjakoski K, Huntsman D, Heikkila P, Lerma E, Kallioniemi A, Rivas C, Foulkes WD, Nevanlinna H, Benitez J. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol, 2005 23 (30): 7503-11.
van der Klift H, Wijnen J, Wagner A, Verkuilen P, Tops C, Otway R, Kohonen-Corish M, Vasen H, Oliani C, Barana D, Moller P, Delozier-Blanchet C, Hutter P, Foulkes WD, Lynch H, Burn J, Moslein G, Fodde R. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible forhereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer, 2005 44 (2): 123-38.
Soravia C, Delozier CD, Dobbie Z, Berthod CR, Arrigoni E, Brundler MA, Blouin JL, Foulkes WD, Hutter P. Double frameshift mutations in APC and MSH2 in the same individual. Int J Colorectal Dis, 2006 21 (1): 79-83.
Barker KT, Foulkes WD, Schwartz CE, Labadie C, Monsell F, Houlston RS, Harper J. Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? J Med Genet, 2006 43(7): 613-614.
Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol, 2006 101 (2): 385-98.
Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, Foulkes WD, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer, 2006 118 (1): 103-7.
McVety S, Li L, Gordon PH, Chong G, Foulkes WD. Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet, 2006 43 (2): 153-6.
Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruszkiewicz A, Barker M, Buchanan D, Young J, Jass JR. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut, 2006 55(10): 1467-1474.
Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Moller P, Apold J, Foulkes WD. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet. 2006 7 (1):15.
McVety S, Li L, Thiffault I, Gordon P.H, MacNamara E, Wong N, Australie K, Kasprzak L, Chong G, Foulkes WD. The value of multi-modal gene screening in HNPCC in Quebec: three mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. Familial Cancer, 2006 5:21-8.
Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson A-M, Foulkes WD, Ghadiran P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. BMC Medical Genetics, 2006 7:23.
Li L, McVety S, Younan R, Du Sart D, Gordon PH, Hutter P, Hogervost FBL, Liang P, Chong G, Foulkes WD. Distinct patterns of Germ-Line Deletions in MLH1 and MLH2 : the Implication of Alu Repetitive Element in the genetic etiology of Lynch Syndrome (HNPCC). Hum Mutations, 2006 27(4): 388.
Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, Foulkes WD, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res, 2006 8(2):R15.
Morel CF, Thomas MA, Cao H, O’Neil CH, Pickering JG, Foulkes WD, Hegele RA. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy (FPLD2). J.Clin.Endocrinol.Metab., 91(7): 2689-2695, 2006.Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer, 2006 118 (9); 2281-4.
Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Rosen B, Kim-Sing C, Isaacs C, Domcheck S, Sun P; for the Hereditary Breast Cancer Clinical Study Group. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet Oncol, 2006 7(5): 402-406.
Goswami RS, Minoo P, Baker K, Chong G, Foulkes WD, Jass JR. Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nat Clin Pract Oncol, 2006 3(5): 281-4.
Galiatsatos P, Kasprzak L, Chong G, Jass JR, Foulkes WD. Multiple primary malignancies in a patient with situs ambiguous. Clin Genet, 2006 69 (6): 528-531.
Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. Fam Cancer, 2006 5(2): 135-142.
Shinto E, Baker K, Tsuda H, Mochizuki H, Ueno H, Matsubara O, Foulkes WD, Jass JR. Tumor Buds Show Reduced Expression of Laminin-5 gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. Dis. Colon and Rectum., 2006 49(8): 1193-1202.
Tischkowitz M, Gologan A, Srolovitz H, Khanna M, Foulkes WD. Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness. Br J Cancer, 2006 95 (2): 243-244.
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with BRCA1 or BRCA2 mutation. JAMA, 2006 296 (2): 185-192.
Baker K, Chong G, Foulkes WD, Jass JR. Transforming growth factor-pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology, 2006 49(4): 371-380.
Oros, KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin P. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet, 2006 70(4):320-329.
Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh C-L, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang B-L, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T LJ, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson B-A, Grönberg H, Camp NJ, Farnham J, Cannon-Albright LA, Catalona WJ, Suarez BK, Roehl KA. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Human Genetics, 2006 120(4):471-485.
Tischkowitz MD, Foulkes WD. The basal phenotype of BRCA1-Related Breast Cancer: Past, Present and Future. Cell Cycle, 5 (9): 963-7, 2006.
Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. Fam Cancer, 2006, 5 (2): 135-142.
Chappuis, PO, Foulkes WD and Provencher, D. Prise en charge du syndrome du cancer du sein et de l’ovaire héréditare. Deuxième partie: Point de vue de l’oncologue et du gynécologue. Le Clinicien 2006, 16: 63-71.
Hamel N, Wong N, Alpert L, Galvez M, Foulkes WD. Mixed ovarian germ cell tumor in a BRCA2 mutation carrier. Int J Gybecol Pathol, 2007 26 (2): 160-4.
McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol, 2007 8(1): 26-34.
Kotsopoulos J, Lubinski J, Lynch H.T, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res., 2007 105(2):221-8.
Refae MA, Wong N, Patenaude F, Bégin LR, Foulkes WD. Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nature Clinical Practice Oncology, 2007 4(4): 256-61.
Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, Van Beers EH, Li, L, Khalil T, Quenneville L, Omeroglu A, Poll A, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod S, Livingston DM, Foulkes WD. Analysis of PALB2/FANCN–associated breast cancer families. Proc Natl Acad Sci USA, 2007 104(16): 6788-93.
Mesurolle B, Kadoch L, El-Khoury M, Lisbona A, Dendukuri N, Foulkes WD. Sonographic Features of Breast Carcinoma Presenting as Masses in BRCA Gene Mutation Carriers. Ultrasound Med, 2007 26(6):817-24.
Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Isaacs WB. Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet, 2007 1;16(11):1271-8.
Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007 7(1):134.
Apicella C, Dowty J, Dite G, Jenkins M, Senie R, Daly M, Andrulis I, John E, Buys S, Li F, Glendon G, Chung W, Ozcelik H, Miron A, Kotar K, Southey M, Foulkes WD, Hopper J. Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clin Genet. 2007 72(2):87-97.
Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle. 2007 6(16):2038-42.
Foulkes WD. P53-master and commander. N Engl J Med., 2007 357(25):2539-41.
Foulkes WD. Clinically relevant biology of hereditary breast cancer. Semin Oncol. 2007 34(5):379-83.
Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E, Robidoux A, Martin G, Bismar TA, Tischkowitz M, Rousseau F, Narod SA. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 2007 9(6):R83.
Zauber P, Sabbath-Solitare M, Stephen PM, Chamberlain R, Chong G, Foulkes WD, Bishop T. Sporadic desmoid tumor in an Ashkenazi patient homozygous for the APC*I1307K gene mutation. Acta Oncol. 47(6):1158-61, 2008.
Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat. 2008 108(3):399-408.
Foulkes WD. BRCA1-sowing the seeds crooked in the furrow. Nat Genet., 2008 40(1):8-9.
Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA. Predictors of Contralateral Prophylactic Mastectomy in Women with a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008 26(7):1093-7.
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA and the Hereditary Breast Cancer Clinical Study Group Breast. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008 122(9):2017-22.
Tischkowitz M, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA. Analysis of the Gene Coding for the BRCA2-Interacting Protein PALB2 in Hereditary Prostate Cancer. The prostate. 2008 68(6):675-8.
Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist S, kConFab, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro ANA, Ladias JAA, Foulkes WD. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket – a multi-modal approach. Eur J Hum Genet. 2008 16(7):820-32.
Hamel N, Tischkowitz M, Foulkes WD. A role for PALB2/FANCN in breast cancer predisposition? Med Sci (Paris). 2008 24(2):120-1.
Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S, Poll A, Eisen A, Gilchrist D, Chudley A, Ghadirian P, Maugard C, Lemire EG, Sun P, Narod S. A family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet, 2008 73(5):474-9.
Vu TT, Zeitouni AG, Tsinalis P, Foulkes WD, Hagr A. Familial clustering of parotid gland lymphoepithelioma in North America. J Otolaryngol., 2008 37(1):23-6.
Palma L, Marcus V, Gilbert L, Chong G, Foulkes WD. Synchronous occult cancers of the endometrium and fallopian tube in an MSH2 mutation carrier at time of prophylactic surgery. Gynecol Oncol. 2008 111(3):575-8.
Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Res Treat. 2008 Mar;114(1):127-35.
Varela-Lema L, Taioli E, Ruano-Ravina A, Barros-Dios JM, Anantharaman D, Benhamou S, Boccia S, Bhisey RA, Cadoni G, Capoluongo E, Chen CJ, Foulkes WD, Goloni-Bertollo EM, Hatagima A, Hayes RB, Katoh T, Koifman S, Lazarus P, Manni JJ, Mahimkar M, Park J, Park KK, Pavarino Bertelli EC, de Souza Fonseca Ribeiro EM, Roy B, Spitz MR, Strange RC, Wei Q, Ragin CC. Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genet Med. 2008 Jun;10(6):369-84
Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control. 2008 Dec;19(10):1111-9.
Tischkowitz MD, Yilmaz A, Chen LQ, Karyadi DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA, Aloyz R, Nelson PS, Hood L, Narod SA, White KA, Ostrander EA, Isaacs WB, Offit K, Cooney KA, Stanford JL, Foulkes WD. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett., 2008 270(1):173-1780.
Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet., 2008 124(1):31-42.
Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer, 2008 99(2):371-4.
Voduc D, Nielsen TO, Cheang MC, Foulkes WD. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol. 2008 39(10):1431-7
Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dörk T, Neal D, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schürmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA; The PRACTICAL Consortium, Eeles RA. Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008 17(8):2052-2061.
Greenblatt MS, Brody LC, Foulkes WD, Genuardi M, Hofstra RM, Olivier M, Plon SE, Sijmons RH, Sinilnikova O, Spurdle AB; IARC Unclassified Genetic Variants Working Group. Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat. 2008 29(11):1273-81.
Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtigian SV; IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008 29(11):1282-91.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008 14(24):8010-8.
Novak DJ, Chen LQ, Ghadirian P, Hamel N, Zhang P, Rossiny V, Cardinal G, Robidoux A, Tonin PN, Rousseau F, Narod SA, Foulkes WD. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women. BMC Cancer. 2008 Aug 15;8:239.
Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. Hereditary Breast Cancer Clinical Study Group. J Natl Cancer Inst. 2008 Oct 1;100(19):1361-7.
Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de Wind N, Hoogerbrugge N, Hogervorst FB; IARC Unclassified Genetic Variants Working Group. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat. 2008 Nov; 29(11):1292-303.
Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008 Nov 13;359(20):2143-53.
Yasmeen A, Liu W, Dekhil H, Kassab A, Aloyz R, Foulkes WD, Al Moustafa AE. BRCA1 mutations contribute to cell motility and invasion by affecting its main regulators. Cell Cycle. 2008 Dec; 7(23):3781-3.
Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008, 124(1):31-42.
Hamel N, Tischkowitz M, Foulkes WD. [A role for PALB2/FANCN in breast cancer predisposition?] Med Sci (Paris). 2008, 24(2):120-1.
Novak DJ, Sabbaghian N, Maillet P, Chappuis PO, Foulkes WD, Tischkowitz M. Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases. Breast Cancer Res Treat. 2009 Sep;117(2):453-9.
Al-Thihli K, Palma L, Marcus V, Cesari M, Kushner YB, Barkun A, Foulkes WD. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol. 6(3):184-9, 2009.
Arnes JB, Bégin LR, Stefansson IM, Brunet JS, Nielsen TO, Foulkes WD, Akslen LA. Expression of EGFR in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol. 2009 Feb;62(2):139-4.
Foulkes WD, Grainge MJ, Rakha EA, Green AR, Ellis IO. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. Breast Cancer Res Treat. 2009 Sep;117(1):199-204
Baker K, Foulkes WD, Jass JR. MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8(+) T cells. Cancer Immunol Immunother. 2009 Jan;58(1):135-44
Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Res Treat. 2009 114(1):127-35.
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009 Apr 1;15(7):2302-10.
Chong G, Jarry J, Marcus V, Thiffault I, Winocour S, Monczak Y, Drouin R, Latreille J, Australie K, Bapat B, Gordon PH, Giguère Y, Gologan A, Galiatsatos P, Jass JR, Wong N, Zaor S, Palma L, Kasprzak L, Tischkowitz M, Foulkes WD. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families. Hum Mutat. 2009 Aug;30(8):E797-812.
Wong Wong Keet A, Al-Rafae M, Chappuis PO, Brunet JS, Ghadirian P, Foulkes WD. Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers. Int J Cancer. 2009 Nov 1;125(9):2236-8.
Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, Foulkes WD, Gallinger S. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009 Sep;137(3):1183-6.
Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat. 2009 Jul 28.
Huang F, Kushner YB, Langleben A, Foulkes WD; Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer. Medscape. Nat Rev Clin Oncol. 2009 Aug;6(8):488-92.
Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009 Oct;41(10):1116-21.
Li L, Biswas K, Habib LA, Kuznetsov SG, Hamel N, Kirchhoff T, Wong N, Armel S, Chong G, Narod SA, Claes K, Offit K, Robson ME, Stauffer S, Sharan SK, Foulkes WD. Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Hum Mutat. 2009 Aug 4. [Epub ahead of print]
Hamilton LJ, Evans AJ, Cornford EJ, Rakha EA, Ellis IO, Foulkes WD. Will MRI screening deliver the expected survival advantage in BRCA 1 carriers? Clin Radiol. 2009 Nov; 64(11):1045-7.
Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet. 2009 Nov; 76(5):421-6.
Foulkes WD, Traffic Control for BRCA1. N Engl J Med. 2010 Feb 25;362(8):755-6.
Foulkes WD, Reis-Filho JS, Narod SA.Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol. 2010 Jun;7(6):348-53.
Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Lange EM, Cooney KA, Tammela TL, Schleutker J, Paiss T, Maier C, Grönberg H, Wiklund F, Emanuelsson M, Farnham JM, Cannon-Albright LA, Camp NJ. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.; International Consortium for Prostate Cancer Genetics. Prostate. 2010 May 15;70(7):735-44.
Foulkes WD, Tomlinson IP. Are we there yet?: journeying along the cancer genetic information superhighway. Curr Opin Genet Dev. 2010 Jun;20(3):197-200.
Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Hereditary Ovarian Cancer Clinical Study Group. Gynecol Oncol. 2010 Aug 1;118(2):155-9.
Greenwood CM, Sun S, Veenstra J, Hamel N, Niell B, Gruber S, Foulkes WD. How old is this mutation? A study of three Ashkenazi Jewish founder mutations. BMC Genetics. 2010, 11:39.
Lachapelle J, Gilbert L, Artho G, Alcindor T, Amre R, Arseneau J, Foulkes WD, et al. "Colonic or Coelomic?" The Lancet. 2010 May; 375(9728): 1844.
Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010 May 25;7(5):e1000279.
Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG. Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Res Treat. 2010 Jun;121(2):347-54.
Dennis J, Ghadirian P, Little J, Lubinski J, Gronwald J, Kim-Sing C, Foulkes W, Moller P, Lynch HT, Neuhausen SL, Domchek S, Armel S, Isaacs C, Tung N, Sweet K, Ainsworth P, Sun P, Krewski D, Narod S; the Hereditary Breast Cancer Clinical Study Group. Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. Breast. 2010 Jun 11. [Epub ahead of print]
Yilmaz A, Hamel N, Schwartz CE, Houlston RS, Harper JI, Foulkes WD. A genome-wide analysis of loss of heterozygosity and chromosomal copy number variation in Proteus syndrome using high-density SNP microarrays. J Hum Genet. 2010 Jun 17. [Epub ahead of print]
Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, Sandelin K, Derossis A, Cody H, Foulkes WD. Is Breast Cancer the Same Disease in Asian and Western Countries? World J Surg. 2010 Jul 7. [Epub ahead of print]
Peixoto A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmão L, Amorim A, van der Hout A, Gerdes AM, Thomassen M, Kruse TA, Cruger D, Sunde L, Bignon YJ, Uhrhammer N, Cornil L, Rouleau E, Lidereau R, Yannoukakos D, Pertesi M, Narod S, Royer R, Costa MM, Lazaro C, Feliubadaló L, Graña B, Blanco I, de la Hoya M, Caldés T, Maillet P, Benais-Pont G, Pardo B, Laitman Y, Friedman E, Velasco EA, Durán M, Miramar MD, Valle AR, Calvo MT, Vega A, Blanco A, Diez O, Gutiérrez-Enríquez S, Balmaña J, Ramon Y Cajal T, Alonso C, Baiget M, Foulkes W, Tischkowitz M, Kyle R, Sabbaghian N, Ashton-Prolla P, Ewald IP, Rajkumar T, Mota-Vieira L, Giannini G, Gulino A, Achatz MI, Carraro DM, de Paillerets BB, Remenieras A, Benson C, Casadei S, King MC, Teugels E, Teixeira MR. International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Res Treat. 2010 Jul 22. [Epub ahead of print]
Foulkes WD. Neonatal Gardner fibroma as the sentinel presentation of severe familial adenomatous polyposis. Pediatrics. [manuscript accepted July 2010]
Foulkes WD et al., Triple-Negative and Basal-Like Breast Cancer. NEJM. [manuscript accepted July 2010]
Peer reviewed and non-peer reviewed book chapters and reviews
Foulkes WD, Lanke E, Jefferies S and Chappuis PO. Genetic susceptibility to carcinoma of the head and neck, stomach and pancreas. In: Genetic predisposition to cancer, second edition, eds. Eeles, RA, Ponder BA, Easton DF and Eng C. Chapman and Hall, 2004, chapter: pp368-391
Rudkin T and Foulkes WD. Multiple Endocrine Neoplasia type 1. In: Genetic predisposition to cancer, second edition, eds. Eeles, RA, Ponder BA, Easton DF and Eng C. Chapman and Hall, 2004, chapter: pp97-104
Foulkes WD and Akslen LA. Pathology of Breast Tumors in Hereditary Breast Cancer in Hereditary breast cancer: risk, prevention and management. Eds Isaacs C and Rebbeck TR. Taylor and Francis, 2007, chapter: pp319-332
Foulkes WD. Clinically relevant biology of hereditary breast cancer. Seminars in Oncology, guest editor, Mark E. Robson, 2007, chapter: pp379-383.
Foulkes WD, Stamp G and Trowsdale J: The molecular genetics of ovarian cancer. In: Ovarian cancer 2, eds. Sharp, F., Mason, W. P. and Creasman, W.T. pp. 23‑33. Chapman and Hall, London, 1992.
Campbell IG, Foulkes WD, Jones T and Trowsdale J: Cloning of genes encoding ovarian carcinoma‑specific antigens. In: Ovarian cancer 2, eds. Sharp, F., Mason, W.P. and Creasman, W. T. pp. 73‑86. Chapman and Hall, London, 1992.
Naylor MS, Stamp GW, Foulkes WD, Eccles D and Balkwill F: Tumor necrosis factor: a role in ovarian cancer? In: Tumor necrosis factor: molecular and cellular biology and clinical relevance, eds. Fiers W, Buurman WA. Pp.199-202. Karger, Basel, 1993.
Foulkes WD and Trowsdale J: Isolating tumour suppressor genes relevant to ovarian carcinoma‑the role of loss of heterozygosity. In: Ovarian Cancer 3, eds, Sharp, F., Mason WP, Berek J and Blackett AD. Pp. 23-38. Chapman and Hall, London, 1995.
Campbell IG, Foulkes WD, Jones TA, Poels LG and Trowsdale J: Cloning and molecular characterisation of monoclonal antibody‑defined ovarian tumour antigens. In: Ovarian Cancer 3, eds, Sharp F, Mason WP, Berek J and Blackett AD. Pp. 53-59. Chapman and Hall, London, 1995.
Foulkes WD and Narod SA: Screening for cancer in high risk populations. In: Cancer screening, ed. Miller AB, Kluwer Academic, Boston, 1996, pp165-182.
Flanders TY and Foulkes WD: Cancers of the digestive system. In: Inherited susceptibility to cancer: clinical, predictive and ethical perspectives. Foulkes WD and SV Hodgson (eds). Cambridge University Press, 1998.
Foulkes WD and Narod SA: Cancers of the breast, ovary and uterus. In: Inherited susceptibility to cancer: clinical, predictive and ethical perspectives. Foulkes WD and SV Hodgson (eds). Cambridge University Press, 1998.
Foulkes WD and Hodgson: Late-breaking developments. In: Inherited susceptibility to cancer: clinical, predictive and ethical perspectives. Foulkes WD and SV Hodgson (eds). Cambridge University Press, 1998.
Foulkes WD and Shelling AN: Moleculr genetics of ovarian cancer: technical overview. In: Methods in Molecular Medicine-Ovarian Cancer. Ed Bartlett J. Humana Press, Totowa, New Jersey, pp. 273-290, 2000.
Chappuis PO and Foulkes WD. Risk assessment and genetic testing. In: Ovarian Cancer, eds. Stack MS and Fishman D. (Cancer Treatment and Research series, Rosen S, series editor) Kluwer Academic, Boston. Volume 107, pages 29-59, 2002.
Chapuis PO and Foulkes WD: Overview of clinical genetics of ovarian cancer. In: Familial Breast And Ovarian Cancer, eds Morrison P, Hodgson SV and Haites N. Cambridge University Press, 2002, chapter 4: pp43-72.
Chappuis PO and Foulkes WD. Management of Hereditary Breast Cancer. In: Familial Breast And Ovarian Cancer, eds Morrison P, Hodgson SV and Haites N. Cambridge University Press, 2002. chapter 15: pp237-274.
Chappuis PO, Stoppa-Lyonnet D, Asselin B and Foulkes WD. Natural history of hereditary breast cancer. In: Familial Breast And Ovarian Cancer, eds Morrison P, Hodgson SV and Haites N. Cambridge University Press, 2002, chapter 6: pp81-107.
Foulkes WD, Lanke E, Jefferies S and Chappuis PO. Genetic susceptibility to carcinoma of the head and neck, stomach and pancreas. In: Genetic predisposition to cancer, second edition, eds. Eeles, RA, Ponder BA, Easton DF and Eng C. Chapman and Hall, 2004, chapter: pp368-391
Rudkin T and Foulkes WD. Multiple Endocrine Neoplasia type 1. In: Genetic predisposition to cancer, second edition, eds. Eeles, RA, Ponder BA, Easton DF and Eng C. Chapman and Hall, 2004, chapter: pp97-104
Foulkes WD. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. Fam Cancer, 5 (2): 135-142, 2006.
Foulkes WD and Akslen LA. Pathology of Breast Tumors in Hereditary Breast Cancer in Hereditary breast cancer: risk, prevention and management. Eds Isaacs C and Rebbeck TR. Taylor and Francis, 2007, chapter: pp319-332
Foulkes WD. Clinically relevant biology of hereditary breast cancer. Semin Oncol. 2007 34(5):379-83.
Book co-authorship
A practical guide to human cancer genetics, third edition: Hodgson SV, Foulkes WD, Eng C and Maher ER. Cambridge University Press, 2006.
Book co-editorship
Foulkes WD and SV Hodgson: Inherited susceptibility to cancer: clinical, predictive and ethical perspectives. Cambridge University Press, 1998.
Cooney K and Foulkes WD. The genetics of male reproductive cancers. Springer, 2009.
Letters (new data or novel hypotheses, not necessarily peer-reviewed)
Foulkes WD, Goddard A and Patel K: Retinoblastoma linked with Seascale. BMJ 1991, 302: 409.
Foulkes WD, Black DM, Solomon E and Trowsdale J: Allele loss on chromosome 17q in sporadic ovarian cancer. Lancet, 1991 338: 444‑445.
Foulkes WD: Tumour suppressor genes in ovarian cancer. BMJ, 1993 307: 1009.
Brunet J-S, Narod SA, Tonin P and Foulkes WD. BRCA1 and ovarian cancer survival. N Engl J Med., 1997 336:1256.
Foulkes WD and Narod SA: Re: Family history of cancer and risk of lung cancer among lifetime non-smoking women in the United States. Am J Epidemiol., 1997 146: 364.
Foulkes WD, Wong N, Rozen F, Brunet, J-S and Narod SA: Breast cancer survival in BRCA1 carriers. Lancet., 1998 351: 1359.
Yuan ZQ, Kasprzak L, Gordon PH, Pinsky L and Foulkes, WD: I1307K APC and hMLH1 mutations in a non-Jewish family with hereditary non-polyposis colorectal cancer. Clin Genet 54: 368-370, 1998.
Chappuis PO, Deschênes J and Foulkes WD. Long-term outcome of invasive breast cancer. Lancet, 2000, 355: 1551.
Julian-Reynier C, Evans G, Foulkes WD, Sobol H. International variation of women’s decisions about prophylactic surgery. Lancet., 2000 356: 1687.
Chappuis PO, Hamel N, Paradis A-J, Deschênes J, Tonin PN, Ghadirian P, Foulkes WD. Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst., 2001 93:152-153.
Goffin JR, Chappuis PO, Wong N, Foulkes WD: Re: Magnetic Resonance Imaging and mammography in Women with a hereditary risk of breast cancer. J Natl Cancer Inst., 2001 93:1754-5.
Andermann A, Thiffault I, Wong N, Gordon P, MacNamara E, Chong G, Foulkes W. Multimodal molecular screening is required to improve the sensitivity of MLH1 and MSH2 mutation analysis. J Clin Oncol., 2002 20:1705-7.
Foulkes WD, Goffin J, Brunet J-S, Bégin LR, Wong N and Chappuis PO. Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of ER status. J Natl Cancer Inst., 2002 94: 1504-1506.
Cremin C, Wong N, Buzaglo K, Paradis A-J and Foulkes WD. Non-ovarian pelvic cancers in BRCA1/2 mutation carriers and BRCAPRO statistical model. J Clin Oncol. 2002 20: 3937-7.
Foulkes WD. Re: Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst., 2003 95: 1344.
Foulkes WD. Re: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst; 2004 96:1040-1.
Foulkes WD, Hamel N, Oros KK, Tonin PN. BRCA mutations and ductal carcinoma in situ. JAMA, 2005 294(5):553-4.
Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS. Are triple negative tumours and basal-like breast cancer synonymous? Breast Cancer Res., 2007 9(6): R80.
Letters (commentary, not peer-reviewed)
Foulkes WD: Breast cancer, desmoid tumours, and familial adenomatous polyposis. Lancet 1993 342: 1560‑1561.
Foulkes WD: The expanded role of NF1. Nature Genet 1993 3: 282.
Foulkes WD: Detection of prostate cancer. BMJ 1995 310: 1139-40.
Foulkes WD, Glendon G and Narod S: Screening for ovarian cancer. JAMA 1995 274: 383.
Rosenblatt DS, Foulkes WD and Narod SA: Genetic screening for breast cancer. N Engl J Med 1996 334: 1200.
Foulkes WD: Pitfalls of Genetic Testing. N Engl J Med 1996 335:1235-6.
Foulkes WD and Narod SA: Ovarian cancer risk and family history. Lancet 1997 349: 878.
Foulkes WD: Survival in hereditary breast cancer. Lancet 1997 350: 366.
Chappuis PO, Narod SA and Foulkes WD: Screening for ovarian cancer. Lancet 1999 354: 509-510.
Foulkes WD, Wong N, Brunet J-S and Narod SA: BRCA mutations and survival in breast cancer. J Clin Oncol. 1998 16: 3206-7.
Sutton M, Laazari K and Foulkes WD: Response to “the traps and pitfalls inherent in the correlation of changes in the fibre diffraction pattern of hair with breast cancer”. Phys Med Biol., 2003 48: L11-L13.
Narasimhadevara R, Pollak MN and Foulkes WD. Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst. 2003 95: 917.
Technical reports
Foulkes WD. Ovarian cancer in Canada. Laboratory Centre for Disease Surveillance, Health Canada,.
Selected abstracts (42 from 1989-2001, not included)
Others
Foulkes WD: The health of the nation. Br. Med. J. 1991, 303: 311‑312.
Conference report:
Foulkes WD: Genetics of Cancer. Lancet 1992, 340: 1402‑1403.
Castration and Sex:
Foulkes WD: Male and female castration. Br. Med. J. 1994, 308:416.
Authorship criteria:
Foulkes WD: and Neylon N: Redefining authorship. Br. Med. J. 1996, 312: 1423.
Book review:
Foulkes WD. Hidden Histories of Science Edited by Robert B Silvers. New York Review Books. Br. Med. J. 1995, 311:1101.